ABCL
NASDAQAbCellera Biologics Inc.
Price$11.80-0.57 (-4.65%)
01:30 PM07:45 PM
News · 26 weeks58+150%
2026-04-192026-10-11
Mix3090d
- Other8(27%)
- SEC Filings8(27%)
- Insider5(17%)
- Earnings4(13%)
- Analyst3(10%)
- Offering2(7%)
Latest news
25 items- ANALYSTUBS initiated coverage on AbCellera Biologics with a new price targetUBS initiated coverage of AbCellera Biologics with a rating of Buy and set a new price target of $18.00
- PRAbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingAbCellera (NASDAQ:ABCL) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San Diego, California. Details on AbCellera’s poster presentation at TMS are as follows: Title: Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABCL635, an NK3R monoclonal antibody antagonist for the treatment of vasomotor symptoms: a Phase 1/2 study Poster ID: P-92 Date and Time: Thursday, October 22 from 6:15 p.m. to 7:15 p.m. PDT Location: Indigo Exhibit Hall (Level 2), Hilton Bayfront AbCellera will present safety, pharmacokinetics, pharmacodynamics, a
- PRAbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026AbCellera (NASDAQ:ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings conference call at 3:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For mor
- ANALYSTAnalyst initiated coverage on AbCellera Biologics with a new price targetAnalyst initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $17.00
- ANALYSTGoldman initiated coverage on AbCellera Biologics with a new price targetGoldman initiated coverage of AbCellera Biologics with a rating of Neutral and set a new price target of $13.00
- PRAbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Oceânico Hotel and Congress Center in Rio de Janeiro, Brazil. Details on AbCellera’s oral presentation at IMS are as follows: Title: Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R Monoclonal Antibody for the Treatment of Vasomotor Symptoms Abstract ID: 16836 Session: Symptoms of Menopause 1 Date and Time: Thursday, October 1 from 8:30 a.m. to 9:30 a.m. GMT-3 Location: Aruba 1, Windsor Oceânico Hotel and Congress Center AbCellera wi
- INSIDERDirector Hayden Michael R bought $570,442 worth of shares (53,613 units at $10.64) (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- PRMost AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that look different are treated as unrelated. That assumption is convenient, and it is often wrong, because biology repeatedly reaches the same function through completely different-looking structures. A c
- INSIDERDirector Montalbano John S. bought $110,300 worth of shares (10,000 units at $11.03), increasing direct ownership by 4% to 251,000 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERChief Financial Officer Booth Andrew bought $383,904 worth of shares (37,200 units at $10.32), increasing direct ownership by 8% to 482,800 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERDirector Hayden Michael R bought $481,033 worth of shares (46,387 units at $10.37) (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECSEC Form 8-K filed by AbCellera Biologics Inc.8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- SECSEC Form 424B5 filed by AbCellera Biologics Inc.424B5 - AbCellera Biologics Inc. (0001703057) (Filer)
- INSIDERDirector Hayden Michael R gifted 50,000 shares (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- PRAbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded WarrantsAbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares at a price to the public of $9.74999 per pre-funded warrant, which represents the per share public offering price of each common share less the $0.00001 per share exercise price for each pre-funded warrant. The gross proceeds to AbCellera from the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and e
- SECSEC Form 424B5 filed by AbCellera Biologics Inc.424B5 - AbCellera Biologics Inc. (0001703057) (Filer)
- PRThese Have the Market Hot Zone Catalysts and SetupsDENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Planet Green Holdings (NYSEAMERICAN:PLAG), NeOnc Technologies (NASDAQ:NTHI), and Quantum Corporation (NASDAQ:QMCO) made nice runs since our midday coverage. While AbCellera Biologics (NASDAQ:ABCL) and Bank of America are among the notable names reaching new 52-week highs Tuesday. However, among the group, NeOnc may be heading into Wednesday with the most clearly defined and potentially binary catalyst: topline Phase 2a data for its brain-cancer program. NeOnc: Wednesday’s Brain-Cancer Data Could be the Biggest Catalyst of the Group NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with a clinical catalyst that could sharply alter the ma
- PRAbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsAbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and pre-funded warrants are being offered by AbCellera. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. AbCellera intends to use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipelin
- PRThe Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major MilestonesDENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) — Today's market is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT) emerging as one of the session's standout movers while biotech names AbCellera Biologics (NASDAQ:ABCL), Silence Therapeutics (NASDAQ:SLN) and NeOnc Technologies (NASDAQ:NTHI) command attention around major clinical milestones. Socket Mobile: The Breakout Stock with a New Distribution Engine Socket Mobile (NASDAQ:SCKT) is kicking off the week as one of the market's most explosive small-cap movers after announcing a strategic partnership with 3Eye Technologies, a value-added dist
- PRAI Found an Influenza Target That Survives Viral MutationAUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. MindWalk Holdings Corp. (NASDAQ:HYFT) has built its entire technology stack around that gap, and in late July it put the result on a stage in front of the AI infrastructure industry. Three Layers, One Idea MindWalk describes itself as a Bio-Native AI c
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability ProfilePhase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose ABCL635 significantly improved sleep and patient global impression of change ABCL635 demonstrated a favorable tolerability profile AbCellera to host a conference call and live webcast today at 4:30 a.m. PT / 7:30 a.m. ET AbCellera (NASDAQ:ABCL) today announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. ABCL635 is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomoto
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET AbCellera (NASDAQ:ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day. A live audio webcast of the investor conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About ABCL635 ABCL635 is a potential first-in-class anti
- SECSEC Form 10-Q filed by AbCellera Biologics Inc.10-Q - AbCellera Biologics Inc. (0001703057) (Filer)
ABCL FAQ
7 questionsWhat does AbCellera Biologics Inc. do?
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.Where does ABCL stock trade?
AbCellera Biologics Inc. (ABCL) is listed on NASDAQ.What sector and industry is ABCL in?
AbCellera Biologics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbCellera Biologics Inc. go public?
AbCellera Biologics Inc. (ABCL) completed its IPO in 2020.What are analysts saying about ABCL?
AbCellera Biologics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $1800.00 price target on 2026-10-12. Recent price targets range from $400.00 to $1800.00.What companies are similar to ABCL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ABCL side-by-side with any of them on Quantisnow.How can I track ABCL on Quantisnow?
Quantisnow aggregates AbCellera Biologics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABCL to receive live email and push alerts on every new disclosure.